PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone610-981-6500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$670,000.00
Profitability
Miscellaneous
Employees22
Next Earnings Date12/5/2019 (Estimated)
OptionableNot Optionable
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions
What is PhaseBio Pharmaceuticals' stock symbol?
PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."
How were PhaseBio Pharmaceuticals' earnings last quarter?
PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.02. The company earned $0.70 million during the quarter, compared to analysts' expectations of $0.13 million. PhaseBio Pharmaceuticals had a negative net margin of 1,447.33% and a negative return on equity of 193.85%. View PhaseBio Pharmaceuticals' Earnings History.
When is PhaseBio Pharmaceuticals' next earnings date?
What price target have analysts set for PHAS?
6 brokers have issued 12-month price objectives for PhaseBio Pharmaceuticals' shares. Their predictions range from $17.00 to $27.00. On average, they expect PhaseBio Pharmaceuticals' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 377.3% from the stock's current price. View Analyst Price Targets for PhaseBio Pharmaceuticals.
What is the consensus analysts' recommendation for PhaseBio Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PhaseBio Pharmaceuticals.
Has PhaseBio Pharmaceuticals been receiving favorable news coverage?
News headlines about PHAS stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PhaseBio Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for PhaseBio Pharmaceuticals.
Are investors shorting PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,760,000 shares, an increase of 49.2% from the August 30th total of 1,180,000 shares. Based on an average daily volume of 315,500 shares, the short-interest ratio is currently 5.6 days. Currently, 12.7% of the shares of the company are sold short. View PhaseBio Pharmaceuticals' Current Options Chain.
Who are some of PhaseBio Pharmaceuticals' key competitors?
Some companies that are related to PhaseBio Pharmaceuticals include ChemoCentryx (CCXI), BioDelivery Sciences International (BDSI), Milestone Pharmaceuticals (MIST), Progenics Pharmaceuticals (PGNX), Intra-Cellular Therapies (ITCI), Crinetics Pharmaceuticals (CRNX), Beyondspring (BYSI), Innate Pharma (IPHYF), Stemline Therapeutics (STML), Collegium Pharmaceutical (COLL), Synthorx (THOR), Evolus (EOLS), AMAG Pharmaceuticals (AMAG), Magenta Therapeutics (MGTA) and Avedro (AVDR).
What other stocks do shareholders of PhaseBio Pharmaceuticals own?
Who are PhaseBio Pharmaceuticals' key executives?
PhaseBio Pharmaceuticals' management team includes the folowing people:
- Mr. Jonathan P. Mow, Pres, CEO & Director (Age 54)
- Mr. John P. Sharp, Chief Financial Officer (Age 54)
- Dr. John S. Lee, Chief Medical Officer (Age 51)
- Mr. Clay Bernardin Thorp, Chairman (Age 51)
- Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 54)
When did PhaseBio Pharmaceuticals IPO?
(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.
How do I buy shares of PhaseBio Pharmaceuticals?
Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is PhaseBio Pharmaceuticals' stock price today?
One share of PHAS stock can currently be purchased for approximately $4.19.
How big of a company is PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals has a market capitalization of $120.25 million and generates $670,000.00 in revenue each year. The company earns $-23,850,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. PhaseBio Pharmaceuticals employs 22 workers across the globe.View Additional Information About PhaseBio Pharmaceuticals.
What is PhaseBio Pharmaceuticals' official website?
How can I contact PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]
MarketBeat Community Rating for PhaseBio Pharmaceuticals (NASDAQ PHAS)
MarketBeat's community ratings are surveys of what our community members think about PhaseBio Pharmaceuticals and other stocks. Vote "Outperform" if you believe PHAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
